The current study aimed to evaluate alterations in double-positive (CD14 + CD16 +) monocytes and sCD163 levels in response to NACT in an attempt to reveal their potential prognostic value in Egyptian breast cancer patients. This evidence concerns the gene CD14 and breast carcinoma.